Early-onset group B streptococcal disease in African countries and maternal vaccination strategies

Frontiers in Public Health

Public Health

Anna C. Seale¹  Vuyelwa Baba²  Ziyaad Dangor³  Gaurav Kwatra⁴ 

[1] Bill and Melinda Gates Foundation, Seattle, WA, United States;London School of Hygiene and Tropical Medicine, London, United Kingdom;Warwick Medical School, University of Warwick, Coventry, United Kingdom;Department of Obstetrics and Gynaecology, University of the Witwatersrand, Johannesburg, South Africa;South African Medical Research Council, Vaccines and Infectious Diseases Analytics Unit, University of the Witwatersrand, Johannesburg, South Africa;South African Medical Research Council, Vaccines and Infectious Diseases Analytics Unit, University of the Witwatersrand, Johannesburg, South Africa;Department of Clinical Microbiology, Christian Medical College, Vellore, India;

关键词: Group B Streptococcus;    Streptococcus agalactiae;    early-onset disease;    neonatal sepsis;    perinatal infections;   

DOI  :  10.3389/fpubh.2023.1214844

 received in 2023-04-30, accepted in 2023-05-31,  发布年份 2023

来源: Frontiers

【 摘 要 】

Invasive group B streptococcal (GBS) disease is the commonest perinatally-acquired bacterial infection in newborns; the burden is higher in African countries where intrapartum antibiotic prophylaxis strategies are not feasible. In sub-Saharan Africa, almost one in four newborns with GBS early-onset disease will demise, and one in ten survivors have moderate or severe neurodevelopmental impairment. A maternal GBS vaccine to prevent invasive GBS disease in infancy is a pragmatic and cost-effective preventative strategy for Africa. Hexavalent polysaccharide protein conjugate and Alpha family surface protein vaccines are undergoing phase II clinical trials. Vaccine licensure may be facilitated by demonstrating safety and immunological correlates/thresholds suggestive of protection against invasive GBS disease. This will then be followed by phase IV effectiveness studies to assess the burden of GBS vaccine preventable disease, including the effect on all-cause neonatal infections, neonatal deaths and stillbirths.

【 授权许可】

Unknown   
Copyright © 2023 Dangor, Seale, Baba and Kwatra.